Literature DB >> 17185412

Identification of the protein receptor binding site of botulinum neurotoxins B and G proves the double-receptor concept.

Andreas Rummel1, Timo Eichner, Tanja Weil, Tino Karnath, Aleksandrs Gutcaits, Stefan Mahrhold, Konrad Sandhoff, Richard L Proia, K Ravi Acharya, Hans Bigalke, Thomas Binz.   

Abstract

Botulinum neurotoxins (BoNTs) cause muscle paralysis by selectively cleaving core components of the vesicular fusion machinery within motoneurons. Complex gangliosides initially bind into a pocket that is conserved among the seven BoNTs and tetanus neurotoxin. Productive neurotoxin uptake also requires protein receptors. The interaction site of the protein receptor within the neurotoxin is currently unknown. We report the identification and characterization of the protein receptor binding site of BoNT/B and BoNT/G. Their protein receptors, synaptotagmins I and II, bind to a pocket at the tip of their H(CC) (C-terminal domain of the C-terminal fragment of the heavy chain) that corresponds to the unique second carbohydrate binding site of tetanus neurotoxin, the sialic acid binding site. Substitution of amino acids in this region impaired binding to synaptotagmins and drastically decreased toxicity at mouse phrenic nerve preparations; CD-spectroscopic analyses evidenced that the secondary structure of the mutated neurotoxins was unaltered. Deactivation of the synaptotagmin binding site by single mutations led to virtually inactive BoNT/B and BoNT/G when assayed at phrenic nerve preparations of complex-ganglioside-deficient mice. Analogously, a BoNT B mutant with deactivated ganglioside and synaptotagmin binding sites lacked appreciable activity at wild-type mouse phrenic nerve preparations. Thus, these data exclude relevant contributions of any cell surface molecule other than one ganglioside and one protein receptor to the entry process of BoNTs, which substantiates the double-receptor concept. The molecular characterization of the synaptotagmin binding site provides the basis for designing a novel class of potent binding inhibitors.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 17185412      PMCID: PMC1716154          DOI: 10.1073/pnas.0609713104

Source DB:  PubMed          Journal:  Proc Natl Acad Sci U S A        ISSN: 0027-8424            Impact factor:   11.205


  36 in total

1.  C-terminal half of tetanus toxin fragment C is sufficient for neuronal binding and interaction with a putative protein receptor.

Authors:  J Herreros; G Lalli; G Schiavo
Journal:  Biochem J       Date:  2000-04-01       Impact factor: 3.857

2.  Structural analysis of the catalytic and binding sites of Clostridium botulinum neurotoxin B.

Authors:  S Swaminathan; S Eswaramoorthy
Journal:  Nat Struct Biol       Date:  2000-08

3.  The fixation of tetanus toxin by ganglioside.

Authors:  W E VAN HEYNINGEN; P A MILLER
Journal:  J Gen Microbiol       Date:  1961-01

4.  SV2 is the protein receptor for botulinum neurotoxin A.

Authors:  Min Dong; Felix Yeh; William H Tepp; Camin Dean; Eric A Johnson; Roger Janz; Edwin R Chapman
Journal:  Science       Date:  2006-03-16       Impact factor: 47.728

5.  Functionality maps of binding sites: a multiple copy simultaneous search method.

Authors:  A Miranker; M Karplus
Journal:  Proteins       Date:  1991

6.  Mice expressing only monosialoganglioside GM3 exhibit lethal audiogenic seizures.

Authors:  H Kawai; M L Allende; R Wada; M Kono; K Sango; C Deng; T Miyakawa; J N Crawley; N Werth; U Bierfreund; K Sandhoff; R L Proia
Journal:  J Biol Chem       Date:  2000-12-27       Impact factor: 5.157

7.  The structures of the H(C) fragment of tetanus toxin with carbohydrate subunit complexes provide insight into ganglioside binding.

Authors:  P Emsley; C Fotinou; I Black; N F Fairweather; I G Charles; C Watts; E Hewitt; N W Isaacs
Journal:  J Biol Chem       Date:  2000-03-24       Impact factor: 5.157

8.  Tetanus toxin fragment C binds to a protein present in neuronal cell lines and motoneurons.

Authors:  J Herreros; G Lalli; C Montecucco; G Schiavo
Journal:  J Neurochem       Date:  2000-05       Impact factor: 5.372

Review 9.  Neurotoxins affecting neuroexocytosis.

Authors:  G Schiavo; M Matteoli; C Montecucco
Journal:  Physiol Rev       Date:  2000-04       Impact factor: 37.312

10.  The synaptic vesicle protein 2C mediates the uptake of botulinum neurotoxin A into phrenic nerves.

Authors:  Stefan Mahrhold; Andreas Rummel; Hans Bigalke; Bazbek Davletov; Thomas Binz
Journal:  FEBS Lett       Date:  2006-03-07       Impact factor: 4.124

View more
  58 in total

1.  Epitope characterization of sero-specific monoclonal antibody to Clostridium botulinum neurotoxin type A.

Authors:  Cindi R Corbett; Erin Ballegeer; Kelly A Weedmark; M D Elias; Fetweh H Al-Saleem; Denise M Ancharski; Lance L Simpson; Jody D Berry
Journal:  Hybridoma (Larchmt)       Date:  2011-12

2.  The case of botulinum toxin in milk: experimental data.

Authors:  Oliver G Weingart; Tanja Schreiber; Conny Mascher; Diana Pauly; Martin B Dorner; Thomas F H Berger; Charlotte Egger; Frank Gessler; Martin J Loessner; Marc-Andre Avondet; Brigitte G Dorner
Journal:  Appl Environ Microbiol       Date:  2010-04-02       Impact factor: 4.792

3.  [Botulinum toxin in the treatment of adult spasticity. An interdisciplinary German 10-point consensus 2010].

Authors:  J Wissel; M auf dem Brinke; M Hecht; C Herrmann; M Huber; S Mehnert; I Reuter; A Schramm; A Stenner; C van der Ven; M Winterholler; A Kupsch
Journal:  Nervenarzt       Date:  2011-04       Impact factor: 1.214

4.  Dynamin inhibition blocks botulinum neurotoxin type A endocytosis in neurons and delays botulism.

Authors:  Callista B Harper; Sally Martin; Tam H Nguyen; Shari J Daniels; Nickolas A Lavidis; Michel R Popoff; Gordana Hadzic; Anna Mariana; Ngoc Chau; Adam McCluskey; Phillip J Robinson; Frederic A Meunier
Journal:  J Biol Chem       Date:  2011-08-05       Impact factor: 5.157

5.  Structural analysis of botulinum neurotoxin type G receptor binding .

Authors:  John Schmitt; Andrew Karalewitz; Desirée A Benefield; Darren J Mushrush; Rory N Pruitt; Benjamin W Spiller; Joseph T Barbieri; D Borden Lacy
Journal:  Biochemistry       Date:  2010-06-29       Impact factor: 3.162

6.  Generation of high-titer neutralizing antibodies against botulinum toxins A, B, and E by DNA electrotransfer.

Authors:  C Trollet; Y Pereira; A Burgain; E Litzler; M Mezrahi; J Seguin; M Manich; M R Popoff; D Scherman; P Bigey
Journal:  Infect Immun       Date:  2009-02-23       Impact factor: 3.441

7.  Identification of the synaptic vesicle glycoprotein 2 receptor binding site in botulinum neurotoxin A.

Authors:  Jasmin Strotmeier; Stefan Mahrhold; Nadja Krez; Constantin Janzen; Jianlong Lou; James D Marks; Thomas Binz; Andreas Rummel
Journal:  FEBS Lett       Date:  2014-02-25       Impact factor: 4.124

Review 8.  Therapeutic use of botulinum toxin in migraine: mechanisms of action.

Authors:  Roshni Ramachandran; Tony L Yaksh
Journal:  Br J Pharmacol       Date:  2014-09       Impact factor: 8.739

9.  Production and evaluation of a recombinant subunit vaccine against botulinum neurotoxin serotype B using a 293E expression system.

Authors:  YunZhou Yu; DanYang Shi; Si Liu; Zheng-Wei Gong; Shuang Wang; ZhiWei Sun
Journal:  Hum Vaccin Immunother       Date:  2015       Impact factor: 3.452

10.  Glycosylated SV2A and SV2B mediate the entry of botulinum neurotoxin E into neurons.

Authors:  Min Dong; Huisheng Liu; William H Tepp; Eric A Johnson; Roger Janz; Edwin R Chapman
Journal:  Mol Biol Cell       Date:  2008-09-24       Impact factor: 4.138

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.